Janus Henderson Group
TAK icon

Janus Henderson Group’s Takeda Pharmaceutical TAK Stock Holding History

Janus Henderson Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-233,950
Closed -$3.1M – 2546
2024
Q4 		$3.1M Sell
233,950
-22,497
-9% -$309K ﹤0.01% 1098
2024
Q3 		$3.65M Sell
256,447
-52,871
-17% -$750K ﹤0.01% 1013
2024
Q2 		$4M Buy
309,318
+111,894
+57% +$1.48M ﹤0.01% 938
2024
Q1 		$2.74M Sell
197,424
-46,828
-19% -$681K ﹤0.01% 1139
2023
Q4 		$3.49M Sell
244,252
-143,766
-37% -$2.04M ﹤0.01% 973
2023
Q3 		$6M Sell
388,018
-8,753
-2% -$136K ﹤0.01% 775
2023
Q2 		$6.23M Sell
396,771
-15,047
-4% -$247K ﹤0.01% 801
2023
Q1 		$6.79M Sell
411,818
-15,842
-4% -$252K ﹤0.01% 794
2022
Q4 		$6.67M Sell
427,660
-14,466
-3% -$202K ﹤0.01% 804
2022
Q3 		$5.73M Sell
442,126
-14,949
-3% -$208K ﹤0.01% 796
2022
Q2 		$6.42M Sell
457,075
-10,685
-2% -$153K ﹤0.01% 792
2022
Q1 		$6.7M Buy
467,760
+57,950
+14% +$851K ﹤0.01% 956
2021
Q4 		$5.59M Sell
409,810
-55,610
-12% -$780K ﹤0.01% 1043
2021
Q3 		$7.62M Sell
465,420
-111,214
-19% -$1.87M ﹤0.01% 957
2021
Q2 		$9.71M Sell
576,634
-74,960
-12% -$1.28M ﹤0.01% 941
2021
Q1 		$11.9M Buy
651,594
+69,243
+12% +$1.25M 0.01% 868
2020
Q4 		$10.6M Sell
582,351
-118,798
-17% -$2.08M ﹤0.01% 860
2020
Q3 		$12.5M Sell
701,149
-54,588
-7% -$994K 0.01% 793
2020
Q2 		$13.6M Buy
755,737
+20,138
+3% +$362K 0.01% 771
2020
Q1 		$11.2M Sell
735,599
-475,057
-39% -$8.61M 0.01% 800
2019
Q4 		$23.9M Sell
1,210,656
-215,825
-15% -$4.13M 0.01% 781
2019
Q3 		$24.5M Sell
1,426,481
-54,006
-4% -$934K 0.01% 780
2019
Q2 		$26.2M Buy
1,480,487
+17,087
+1% +$311K 0.01% 735
2019
Q1 		$29.8M Buy
1,463,400
+781,068
+114% +$15.7M 0.02% 697
2018
Q4 		$11.5M Buy
+682,332
New +$11.5M 0.01% 875

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Janus Henderson Group's TAK Position: Q1 2025 in Review

Janus Henderson Group sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 233,950 shares — an estimated $3.1M sold.

Janus Henderson Group first reported a position in TAK in Q4 2018 and held it in 25 quarters. The position peaked at $29.8M in Q1 2019. 309 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

  • Janus Henderson Group reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 233,950 Takeda Pharmaceutical shares in Q1 2025, an estimated $3.1M.
  • Janus Henderson Group first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 25 quarters.
  • Janus Henderson Group's Takeda Pharmaceutical position peaked at $29.8M in Q1 2019.
  • 309 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.